Clinical Trials Logo

Stage III Bladder Cancer clinical trials

View clinical trials related to Stage III Bladder Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02735512 Terminated - Clinical trials for Stage III Bladder Cancer

MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer

Start date: March 1, 2016
Phase:
Study type: Observational

This pilot research trial studies how well myeloid derived suppressor cells (MDSC) clinical assay works in finding and monitoring cancer cells in blood and urine samples from patients with or without localized or metastatic bladder cancer. Studying samples of blood and urine from patients with or without bladder cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer and may help doctors improve ways to diagnose and treat patients.

NCT ID: NCT02316548 Terminated - Clinical trials for Stage IV Bladder Cancer

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

Start date: February 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies the side effects and how well postoperative intensity modulated radiotherapy works after surgery in treating patients with urothelial bladder cancer. Radiation therapy uses high energy x-rays to kill tumor cells left behind in the pelvis after surgery. It is not yet known whether surgery followed by radiotherapy is more effective than surgery alone in treating patients with urothelial bladder cancer.

NCT ID: NCT02122172 Terminated - Clinical trials for Stage IV Bladder Cancer

Afatinib in Advanced Refractory Urothelial Cancer

Start date: September 13, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.

NCT ID: NCT01954173 Terminated - Bladder Cancer Clinical Trials

Adjuvant Radiation for High Risk Bladder Cancer

Start date: July 22, 2013
Phase: N/A
Study type: Interventional

This phase II trial studies how well modern, conformal radiation therapy after surgery works in treating patients with high-risk bladder cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

NCT ID: NCT01611662 Terminated - Clinical trials for Stage III Bladder Cancer

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Start date: May 29, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to find out what effects, good and/or bad, dose-dense (every 14 days) chemotherapy with gemcitabine (gemcitabine hydrochloride) and cisplatin given before surgery have on patients and their muscle invasive bladder cancer.

NCT ID: NCT01382706 Terminated - Clinical trials for Stage IV Bladder Cancer

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Start date: June 13, 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel and lapatinib ditosylate together may kill more tumor cells.

NCT ID: NCT01282333 Terminated - Clinical trials for Stage IV Non-small Cell Lung Cancer

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This phase I clinical trial is studying the side effects and best dose of veliparib and gemcitabine hydrochloride when given with cisplatin in treating patients with advanced biliary, pancreatic, urothelial, or non-small cell lung cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Veliparib may help cisplatin and gemcitabine hydrochloride work better by making tumor cells more sensitive to the drugs.

NCT ID: NCT00112905 Terminated - Clinical trials for Stage IV Bladder Cancer

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Start date: October 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with progressive regional or metastatic cancer of the urothelium. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00072137 Terminated - Clinical trials for Bladder Urothelial Carcinoma

Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy

Start date: October 2003
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of vaccine therapy given directly into the bladder in treating patients who are undergoing surgery to remove all or part of the bladder. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Giving a vaccine directly into the bladder before surgery may cause a stronger immune response and keep tumor cells from coming back after surgery.